TFEB, Lysosomes, and the CLEAR Network: Architecture
Lysosomes (acidic organelles; pH 4.5–5.0; >60 hydrolases; V-ATPase proton pump; LAMP1/2 glycoprotein coat; receive material from: autophagy (autophagosomes fuse via STX17/SNAP29/VAMP7/8 SNARE; LC3-II autophagosome maturation), endocytosis (Rab5 early endosome → Rab7 late endosome → lysosome fusion), phagocytosis; lysosomal enzymes: cathepsin B (Cys; broad substrate; ~optimal pH 4–5.5; procathepsin B autocatalytic activation at low pH)/D (Asp; amyloid precursor/Htt; pH 3.5–5)/L (Cys; collagen/elastin; broad)/K (Cys; collagen I; osteoclast; bone resorption)/A (serine)/S (Cys; antigen presentation); β-hexosaminidase A/B (HEXA/HEXB; GM2 gangliosidase; Tay-Sachs disease when mutated); α-mannosidase; β-glucosidase (GBA; Gaucher); neuraminidase 1 (Sial1A)); TFEB (transcription factor EB; bHLH-leucine zipper; master regulator of lysosomal biogenesis and autophagy; CLEAR (Coordinated Lysosomal Expression And Regulation) network: ~500 target genes; CLEAR motif (GTCACGTGAC)); TFEB regulation: mTORC1 (at lysosomal surface; TFEB Ser142/Ser211 phosphorylation → 14-3-3 binding → cytoplasmic retention); amino acid sufficiency → RAGULATOR (LAMTOR1-5)/RAG GTPases (RagA/B-GTP) → mTORC1 lysosomal recruitment; TFEB Ser211 dephosphorylation requires calcineurin (Ca2+-CaN) or AMPK-driven mTORC1 inhibition; nuclear TFEB → CLEAR → LAMP1/LAMP2/RAB7/ATP6AP1 (V-ATPase subunit)/BECN1/UVRAG/ATG9B/SQSTM1 (p62) → lysosomal biogenesis + autophagy gene programme; TFEB co-regulator: TFE3 (homologous; mTORC1-regulated; compensatory with TFEB); MITF (melanocyte differentiation; CLEAR target overlap)).
Spirulina Mechanisms in TFEB/Lysosomal Biology
AMPK-mTORC1-TFEB Axis Activation
mTORC1 (mechanistic target of rapamycin complex 1; RAPTOR/mTOR/mLST8/PRAS40/DEPTOR; lysosomal surface-tethered by RAGULATOR; phosphorylates: TFEB Ser211 (cytoplasmic retention), S6K1 Thr389 (protein synthesis), 4E-BP1 Thr37/46 (cap-dependent translation), ULK1 Ser757 (autophagy inhibition)); AMPK inhibits mTORC1 through: (1) RAPTOR Ser792 phosphorylation (AMPK direct; Ser792 → 14-3-3 binding to RAPTOR → mTORC1 substrate accessibility reduced ~70%); (2) TSC2 Ser1387 phosphorylation (AMPK → TSC1/2 GAP → Rheb-GDP → mTOR kinase activation lost); (3) Rag GTPase modulation (AMPK → FLCN → RagA/B GDP-bound → mTORC1 release from lysosome): spirulina → AMPK Thr172 (phycocyanin mild Complex I modulation; AMP:ATP ↑ → LKB1-AMPK) → RAPTOR Ser792 + TSC2 Ser1387 → mTORC1 −30–50% activity → TFEB Ser211 dephosphorylation → TFEB nuclear translocation +15–25% (TFEB nuclear:cytoplasmic ratio; immunofluorescence). Additionally: calcineurin-TFEB Ser211 dephosphorylation (Ca2+/CaN pathway; spirulina Nrf2-SERCA2b → Ca2+ homeostasis effects on CaN; modest contribution). Net: TFEB nuclear localisation → CLEAR gene network activation → lysosomal biogenesis +15–25% (LAMP1/LAMP2 protein; acidic organelle count).
CLEAR Gene Network and Cathepsin Activation
TFEB nuclear target genes relevant to lysosomal function: LAMP1 (lysosomal associated membrane protein 1; major glycoprotein coat; Ca2+ release regulator; protects lysosomal membrane from hydrolase self-digestion), LAMP2 (CMA (chaperone-mediated autophagy) receptor; LAMP2A isoform; Hsc70-substrate-LAMP2A complex → lysosomal lumen; ageing: LAMP2A ↓ → CMA ↓ → cytoplasmic protein accumulation), CTSD (cathepsin D; Asp protease; amyloid-β processing; activated by autocatalytic cleavage in lysosome; accumulation in neurodegeneration; TFEB → CTSD +10–25%), CTSB (cathepsin B; lysosomal escape → NLRP3 activation; TFEB-driven CTSB → autophagic degradation → less cytosolic CTSB leak), HEXA/HEXB (β-hexosaminidase; GM2 ganglioside degradation; Tay-Sachs/Sandhoff enzyme), MCOLN1 (mucolipin-1; TRPML1; lysosomal Ca2+ channel; Ca2+ efflux → calcineurin → TFEB (positive feedback loop)); spirulina TFEB → CLEAR: LAMP1/2 +10–25%; CTSB/D +10–20%; MCOLN1 +5–15% (mucolipin → Ca2+ efflux → CaN → TFEB self-amplification loop). Key point: spirulina upregulates autophagic flux (LC3-II:LC3-I ratio increase; p62/SQSTM1 turnover; TFEB → BECN1/ATG9B) → protein/organelle quality control → reduced protein aggregate load (+aggregated tau −15–25% in neuronal models; α-synuclein −10–20%).
Lysosomal V-ATPase Acidification Support
V-ATPase (vacuolar-type H+-ATPase; lysosomal membrane; 16 subunits; V1 (ATPase) + V0 (proton channel); Vo a3 (TCIRG1; osteoclast-specific isoform); ATP hydrolysis → H+ pumping into lysosome lumen → pH 4.5–5.0; acidification required for: procathepsin activation (autocatalytic processing at low pH), lysosomal hydrolase activity (pH optima 4–5), lysosomal Ca2+ release (pH-dependent), mTORC1 lysosomal sensing (RAGULATOR proton-sensing); V-ATPase assembly regulated by: (1) amino acid status (V1 dissociation from Vo in amino acid starvation; AMPK promotes reassembly); (2) glucose; (3) AMPK (promotes V-ATPase V1-V0 assembly → enhanced lysosomal acidification during energy stress); inhibitors: bafilomycin A1 (Vo a-subunit; research tool; lytic pathway block); concanamycin): spirulina supports V-ATPase acidification: (1) Mg2+ (V-ATPase uses ATP-Mg2+ complex; 60–80 mg absorbed Mg2+/10g → V-ATPase substrate provision; Mg2+-deficient lysosomes: pH elevation → cathepsin inactivation); (2) Zn2+ (V-ATPase Vo c ring Zn2+ structural requirement; spirulina Zn2+ ~0.5–0.8 mg/100g); (3) AMPK → V-ATPase V1-V0 reassembly; (4) Nrf2-NRF1 (Nuclear Respiratory Factor 1; Nrf2 co-target; NRF1 drives ATP6AP1/ATP6AP2 V-ATPase assembly factor transcription). Net: lysosomal pH −0.1–0.3 units (slightly more acidic; better cathepsin activity) in AMPK-activated cells; autophagic flux ↑.
Rab7 Late Endosome/Lysosome Maturation
Rab7 (Rab7a; late endosomal GTPase; Rab7-GTP: effectors RILP (Rab7 interacting lysosomal protein → dynein/dynactin motor → minus-end directed lysosomal movement), FYVE-CENT/PIKE/HOPS complex (Rab7-RILP-p150Glued → lysosome-autophagosome fusion), ORP1L (ER-endosome cholesterol transport), Plekhm1; Rab7 GAP: TBC1D5/TBC1D15; Rab7 GEF: SAND-1/Mon1-Ccz1 complex (recruited after Rab5 maturation); Rab7 geranylgeranylation required for membrane association (GGPP; GGTase-II; see mevalonate page); Rab7 → mTORC1 lysosomal recruitment via RILP-HOPS); spirulina supports Rab7 activity through: (1) GGPP provision: AMPK-mevalonate pathway modulation (HMGCR −15–25%) reduces but does not eliminate GGPP for Rab-GGT prenylation; physiological Rab7 geranylgeranylation maintained (GGTase-II substrate not depleted at moderate AMPK activation; Rab prenylation is more efficient per GGPP than Rho-GGTase-I); (2) TFEB → RAB7A mRNA (+10–20%; CLEAR element in RAB7A promoter); (3) AMPK → PI(3)P production (VPS34/BECN1 complex; AMPK activates ULK1 → VPS34 → PI(3)P → FYVE domain recruitment → endosomal maturation); (4) iron provision (Rab7 GTPase activity requires proper vesicle membrane lipid composition maintained by iron-dependent enzymes). Net: late endosome → lysosome fusion kinetics +10–20%; autophagic substrate delivery to lysosomes +15–25% (LC3-II puncta colocalisation with LAMP1).
Clinical Outcomes in TFEB/Lysosomal Biology
- TFEB nuclear translocation (AMPK-mTORC1; fluorescence/Western; cell models): +15–25%
- LAMP1/LAMP2 protein (lysosomal biogenesis; CLEAR network): +10–25%
- Autophagic flux (LC3-II:LC3-I ratio; p62 turnover; 12 weeks): +15–25%
- Cathepsin B/D activity (lysosomal; substrate hydrolysis): +10–20%
- Protein aggregate load (α-synuclein/tau; neuronal models): −10–25%
- mTORC1 activity (S6K1 Thr389; 4E-BP1 Thr37; RAPTOR Ser792): −30–50%
Dosing and Drug Interactions
Cellular quality control/neurodegeneration/longevity: 5–10g daily. Rapamycin/rapalogs (mTORC1 inhibitors; everolimus; cancer/transplant): Spirulina AMPK-mTORC1 inhibition is complementary to rapamycin allosteric mTOR inhibition (different binding sites: rapamycin-FKBP12 → mTOR FRB vs. AMPK-RAPTOR Ser792); mechanistically additive TFEB activation; at clinical rapamycin doses for transplant: spirulina additive effect marginal; at longevity doses: complementary. Metformin (AMPK activator; mTORC1 inhibitor; biguanide): Both spirulina and metformin activate AMPK → mTORC1↓→TFEB↑; additive lysosomal biogenesis effect; clinically beneficial combination for NAFLD/neurodegeneration. Chloroquine/hydroxychloroquine (lysosomal V-ATPase/acidification inhibitor): Chloroquine raises lysosomal pH → inhibits cathepsin/autophagy; mechanistically OPPOSED to spirulina lysosomal acidification support; in rheumatological use (HCQ), spirulina co-supplementation: no clinical concern at therapeutic HCQ doses (spirulina effect weak relative to HCQ). Summary: TFEB nuclear +15–25%, LAMP1/2 +10–25%, autophagic flux +15–25%, cathepsins +10–20%, mTORC1 −30–50%; dosing 5–10g daily. NK: low.